Tenaya Therapeutics TNYA Stock
Tenaya Therapeutics Price Chart
Tenaya Therapeutics TNYA Financial and Trading Overview
| Tenaya Therapeutics stock price | 0.35 USD |
| Previous Close | 0.37 USD |
| Open | 0.37 USD |
| Bid | 0.34 USD x 100 |
| Ask | 0.36 USD x 100 |
| Day's Range | 0.34 - 0.38 USD |
| 52 Week Range | 0.3 - 1.54 USD |
| Volume | 2.22M USD |
| Avg. Volume | 2.84M USD |
| Market Cap | 79.21M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 USD |
TNYA Valuation Measures
| Enterprise Value | 15.26M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.96527773 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 26.123043 |
| Price/Book (mrq) | 1.453975 |
| Enterprise Value/Revenue | 5.033 |
| Enterprise Value/EBITDA | -0.204 |
Trading Information
Tenaya Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -72.91% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 1.54 USD |
| 52 Week Low | 0.3 USD |
| 50-Day Moving Average | 0.52 USD |
| 200-Day Moving Average | 0.7 USD |
TNYA Share Statistics
| Avg. Volume (3 month) | 2.84M USD |
| Avg. Daily Volume (10-Days) | 2.67M USD |
| Shares Outstanding | 227.93M |
| Float | 215.21M |
| Short Ratio | 6.28 |
| % Held by Insiders | 0.44% |
| % Held by Institutions | 47.95% |
| Shares Short | 23.41M |
| Short % of Float | 13.15% |
| Short % of Shares Outstanding | 10.26% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2656.89% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -55.43% |
| Return on Equity (ttm) | -148.16% |
Income Statement
| Revenue (ttm) | 3.03M USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 3.03M USD |
| EBITDA | -74875000 USD |
| Net Income Avi to Common (ttm) | -101778000 USD |
| Diluted EPS (ttm) | -0.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 66.8M USD |
| Total Cash Per Share (mrq) | 0.29 USD |
| Total Debt (mrq) | 2.85M USD |
| Total Debt/Equity (mrq) | 5.23 USD |
| Current Ratio (mrq) | 3.776 |
| Book Value Per Share (mrq) | 0.239 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -54410000 USD |
| Levered Free Cash Flow (ttm) | -25046124 USD |
Profile of Tenaya Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 171 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 825 6990 |
| Website | https://www.tenayatherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 70 |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Q&A For Tenaya Therapeutics Stock
What is a current TNYA stock price?
Tenaya Therapeutics TNYA stock price today per share is 0.35 USD.
How to purchase Tenaya Therapeutics stock?
You can buy TNYA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tenaya Therapeutics?
The stock symbol or ticker of Tenaya Therapeutics is TNYA.
Which industry does the Tenaya Therapeutics company belong to?
The Tenaya Therapeutics industry is Biotechnology.
How many shares does Tenaya Therapeutics have in circulation?
The max supply of Tenaya Therapeutics shares is 227.93M.
What is Tenaya Therapeutics Price to Earnings Ratio (PE Ratio)?
Tenaya Therapeutics PE Ratio is now.
What was Tenaya Therapeutics earnings per share over the trailing 12 months (TTM)?
Tenaya Therapeutics EPS is -0.48 USD over the trailing 12 months.
Which sector does the Tenaya Therapeutics company belong to?
The Tenaya Therapeutics sector is Healthcare.
Tenaya Therapeutics TNYA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
24959.17 USD — |
-1.6
|
3.09B USD — | 24888.98 USD — | 25423.09 USD — | — - | 3.09B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12287.29 USD — |
-1.63
|
— — | 12257.24 USD — | 12520.36 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7172.47 USD — |
-1.04
|
— — | 7149.19 USD — | 7222.99 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1362.42 USD — |
-0.77
|
— — | 1358.68 USD — | 1371.59 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
